Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Atea Pharmaceuticals, Inc. (AVIR)

Atea Pharmaceuticals Q4 net loss widens to $44.9 million; full-year loss narrows

Mixed Impact 3 of 5 earnings Written later

Atea Pharmaceuticals reported a fourth-quarter 2025 net loss of $44.9 million, or $0.57 per share, up from $33.5 million, or $0.40 per share, a year earlier. For the full year, the net loss narrowed to $158.3 million, or $1.94 per share, from $168.4 million, or $2.00 per share. Cash and investments fell to $301.8 million at December 31, 2025, from $454.7 million, and the filing gives no revenue figure.

Key points

  • Q4 2025 research and development expenses rose to $47.8 million from $25.7 million, partly due to HCV Phase 3 spending and a milestone under the Merck License Agreement.
  • Full-year 2025 general and administrative expenses fell to $32.9 million from $48.8 million, mainly on lower stock-based compensation.
  • Income tax benefits of $6.8 million in Q4 and $6.2 million for the full year were primarily from recognition of previously unrecognized tax benefits.
  • C-BEYOND topline results are expected mid-2026 and C-FORWARD topline results around year-end 2026.

The filing

CompanyAtea Pharmaceuticals, Inc. (AVIR)
Form8-K, current report
Filed with the SECMar 5, 2026, 4:11 PM ET
Accession number0001193125-26-093961

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on March 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.